Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + fluorouracil + tamoxifen
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of four drugs—cyclophosphamide, epirubicin, fluorouracil (also known as 5-fluorouracil), and tamoxifen—used primarily in the treatment of breast cancer. Cyclophosphamide is an alkylating agent that interferes with DNA replication. Epirubicin is an anthracycline antibiotic that inhibits topoisomerase II and intercalates into DNA. Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and disrupts DNA synthesis. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an antagonist on estrogen receptors in breast tissue. The combination of these agents provides both cytotoxic chemotherapy (CEF) and hormonal therapy (tamoxifen), improving survival outcomes for patients with node-positive or metastatic breast cancer[1][2][3]. This regimen has been studied extensively in randomized clinical trials.
- Other names
- cyclophosphamide, epirubicin, 5-fluorouracil, tamoxifenCEF plus tamoxifen
02
Targets
DNAESR1 (ERα)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + fluorouracil + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + fluorouracil + tamoxifen.